Open AccessInduction of Cytotoxic T Lymphocytes Specific to Malignant Glioma Using T2 Cells Pulsed with HLA‐A2‐restricted Interleukin‐13 Receptor α2 Peptide in vitro
Author(s) -
JIANG Xiaobing,
LU Xiaoling,
LIU Ru'en,
ZHANG Fangcheng,
ZHAO Hongyang
Publication year - 2007
Publication title -
acta biochimica et biophysica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.771
H-Index - 57
eISSN - 1745-7270
pISSN - 1672-9145
DOI - 10.1111/j.1745-7270.2007.00331.x
Subject(s) - cytotoxic t cell , ctl* , glioma , epitope , monoclonal antibody , immunotherapy , antigen , biology , human leukocyte antigen , cancer research , immunology , microbiology and biotechnology , immune system , antibody , in vitro , cd8 , biochemistry
Interleukin‐13 receptor α2 (IL‐13Rα2) is a glioma‐restricted cell‐surface epitope not otherwise detected within the central nervous system. The present study is a report of a novel approach of targeting malignant glioma with IL‐13Rα2‐specific cytotoxic T lymphocyte (CTL) induced from the peripheral blood mononuclear cells of healthy donors by multiple stimulations with human leukocyte antigen (HLA)‐A2‐restricted IL‐13Rα2 345‐353 peptide‐pulsed T2 cells. The induced CTL showed specific lysis against T2 cells pulsed with the peptide and HLA‐A2 + glioma cells expressing IL‐13Rα2 345‐353 , while HLA‐A2 glioma cell lines that express IL‐13Rα2 345‐353 could not be recognized by CTL. The peptide‐specific activity was inhibited by anti‐HLA class I monoclonal antibody. These results suggest that the induced CTL specific for IL‐13Rα2 345‐353 peptide could be a potential target of specific immunotherapy for HLA‐A2 patients with malignant glioma.